Educational Notice

This article is written for researchers, clinicians, and informed consumers seeking to understand the published evidence on PT-141 (bremelanotide). It is not medical advice, a treatment recommendation, or a substitute for professional consultation. PT-141 is an FDA-approved prescription medication; its use requires physician supervision. Off-label use in men has not received FDA approval. Consult a qualified physician before making any decisions.

A Comprehensive Evidence Review — Central Mechanism, RECONNECT Trial Data, HSDD in Women, Off-Label Use in Men, and the PDE5 Inhibitor Comparison

PT-141 (bremelanotide) occupies a genuinely unusual position in pharmacology: it is an FDA-approved drug for a condition — hypoactive sexual desire disorder in women — that was largely dismissed as a legitimate medical target for most of the twentieth century. The compound’s path to approval is equally unusual. It originated as a metabolite of Melanotan II, a tanning peptide being studied at the University of Arizona, when researchers noticed that male subjects in early human trials experienced spontaneous erections and reported markedly increased libido. The sexual effects were an accidental discovery. What followed was two decades of development work to isolate and refine those effects into a specific, approvable drug — stripping away the tanning activity, improving tolerability, and running the controlled trials needed to demonstrate efficacy in a patient population that had no approved pharmacological options.

The result is Vyleesi (bremelanotide injection, 1.75 mg SC), approved by the FDA in June 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). It is the second approved pharmacological treatment for HSDD — the first being flibanserin (Addyi), a serotonin receptor modulator approved in 2015 — and the only one that works through the melanocortin receptor system. It is also the only approved drug for female sexual dysfunction that addresses desire rather than a mechanical or vascular component of sexual response.

PT-141 works through a mechanism that is categorically different from every other approach to sexual dysfunction pharmacology. PDE5 inhibitors (sildenafil, tadalafil, vardenafil) work peripherally — they inhibit cGMP breakdown in vascular smooth muscle, improving blood flow to tissue that is already aroused. PT-141 works centrally — it activates MC3R and MC4R in the hypothalamus and limbic system, the neural circuits that generate sexual desire and motivation before any peripheral response occurs. The practical significance of this distinction is substantial: PT-141 can produce sexual arousal in individuals whose sexual dysfunction is rooted in desire deficit rather than mechanical failure, in individuals with cardiovascular disease that limits PDE5 inhibitor effectiveness, and in women, for whom PDE5 inhibitors have demonstrated limited efficacy in most indications.

Quick Facts

Generic Name

Bremelanotide

Brand Name

Vyleesi (AMAG Pharmaceuticals / Palatin Technologies)

FDA Approval

June 2019 — HSDD in premenopausal women (acquired, generalized)

Mechanism Class

MC3R / MC4R agonist — central hypothalamic sexual arousal activation

Evidence Tier

Approved Drug — Phase III RECONNECT trial data in women; Phase I/II in men

WADA Status

Not prohibited

Approved Dose

1.75 mg SC injection, as needed, 45 min before anticipated sexual activity; max 1 dose per 24 hours; max 8 doses per month

Key Precautions

Transient hypertension — measure BP before each dose; nausea (common); contraindicated with CV disease where BP elevation is risky; hyperpigmentation with chronic use

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

What Is PT-141?

PT-141 is the research designation for bremelanotide, a cyclic heptapeptide melanocortin receptor agonist that was developed by Palatin Technologies from Melanotan II (MT-II) research conducted at the University of Arizona. The compound shares MT-II’s core cyclic heptapeptide scaffold but differs in receptor selectivity: where MT-II is a pan-agonist activating MC1R, MC3R, MC4R, and MC5R with roughly comparable potency, bremelanotide was engineered to preferentially activate MC3R and MC4R — the receptors governing sexual arousal and appetite — while minimizing MC1R activity, which is responsible for the tanning and melanocytic nevi effects that made MT-II a problematic development candidate.

The chemical difference between MT-II and PT-141 is subtle — a hydroxyl group on the proline residue — but pharmacologically significant. This modification reduces MC1R binding affinity substantially while maintaining MC3R/MC4R agonism, producing a compound that retains the desired central sexual effects while shedding the tanning activity and the associated melanoma risk signal that limited MT-II’s development. The result is a molecule with a cleaner, more targetable pharmacological profile suited to clinical development for a specific indication.

Plain English

PT-141 was carved out of a tanning peptide. Researchers found that the tanning peptide (MT-II) had a powerful sexual arousal side effect, then spent 20 years figuring out how to keep the arousal effect while removing the tanning effect. PT-141 is what they ended up with — a compound that activates the brain’s desire circuitry without much effect on skin pigmentation.

Origins: From MT-II to Bremelanotide

The origin story of PT-141 is one of the more unusual in pharmaceutical history. Victor Hruby’s group at the University of Arizona synthesized MT-II in the late 1980s as a tool to study the melanocortin system and as a potential pharmacological tanning agent. Early Phase I studies in the mid-1990s revealed an unexpected side effect: male subjects experienced spontaneous erections, sometimes prolonged, and reported increased sexual desire. One early trial participant self-administered a dose substantially above the study protocol and experienced an eight-hour erection requiring emergency medical treatment. The clinical observations were documented in the trial reports and published.

Palatin Technologies licensed the MT-II IP and began the development program that would become PT-141. The initial development target was erectile dysfunction — a well-defined, commercially validated market with established endpoints. Early Phase I/II studies of MT-II and then PT-141 in men with erectile dysfunction confirmed the central arousal mechanism and demonstrated efficacy signals, but the nausea burden and blood pressure effects created tolerability challenges. An intranasal formulation was developed and studied, producing the PT-141 nasal spray that advanced through Phase II clinical trials in men. That program was ultimately discontinued not for efficacy failure but for tolerability and commercial reasons.

The program pivot to female sexual dysfunction — specifically HSDD — proved to be the right strategic call. HSDD had no approved pharmacological treatment until flibanserin in 2015, the unmet medical need was substantial, and the central desire-activating mechanism of PT-141 was a better mechanistic fit for HSDD (a condition of desire deficit) than for erectile dysfunction (a condition where desire is often intact but mechanical response is impaired). Palatin developed the SC injection formulation (1.75 mg), ran the Phase III RECONNECT trials, and received FDA approval in June 2019. The full development program from accidental observation to approval spanned approximately 25 years.

Understanding HSDD: The Condition PT-141 Treats

Hypoactive sexual desire disorder (HSDD) is defined in DSM-5 as persistently or recurrently deficient sexual thoughts, fantasies, and desire for sexual activity that causes marked distress or interpersonal difficulty, and that is not better explained by another mental disorder, substance use, medication effects, or another medical condition. The diagnosis requires that the symptoms not be caused by relationship problems, life stressors, or other identifiable non-psychiatric factors — though these can coexist and complicate assessment. HSDD is classified as acquired (developed after a period of normal sexual function) or lifelong, and as generalized (occurring in all contexts) or situational (context-specific). PT-141 is approved only for the acquired, generalized subtype in premenopausal women.

Prevalence estimates for HSDD in women vary considerably by study methodology and diagnostic criteria, but population surveys consistently identify it as the most common female sexual dysfunction — affecting approximately 8–10% of premenopausal women and higher proportions of perimenopausal and postmenopausal women. The distress criterion is critical: many women have low sexual desire without experiencing it as a problem. HSDD specifically captures those for whom the desire deficit causes meaningful distress. This subset is substantial — estimates place it at several million women in the United States — and represents a genuine unmet medical need.

The pathophysiology of HSDD is not fully characterized. Leading models propose an imbalance between excitatory and inhibitory sexual neural systems: the central excitatory system (involving dopamine, oxytocin, and melanocortin pathways) is underactive, or the central inhibitory system (involving serotonin and opioid pathways) is overactive, or both. This dual control model, developed by Bancroft and Janssen and influential in the field, provides the mechanistic context for both approved HSDD treatments: flibanserin addresses the serotonergic inhibitory pathway, and PT-141 activates the melanocortin excitatory pathway. They work through different mechanisms and are not mutually exclusive treatments.

Plain English

HSDD isn’t low libido from stress or relationship problems — it’s a persistent, distressing absence of sexual desire that isn’t explained by other factors. Think of the brain’s sexual motivation system as having an accelerator and a brake. In HSDD, either the accelerator is too weak or the brake is too strong. PT-141 pushes the accelerator. The other approved drug, flibanserin, releases the brake. Different mechanisms, potentially complementary in some patients.

Mechanism of Action: Central Melanocortin Arousal

PT-141’s sexual arousal effects are mediated primarily through MC4R (melanocortin receptor 4) in the hypothalamus and limbic system, with MC3R contributing to the overall response. MC4R is densely expressed in the paraventricular nucleus (PVN) of the hypothalamus, the medial preoptic area (MPOA), and the ventromedial hypothalamus — regions that are established regulators of sexual motivation and behavior in animal models and human neuroimaging studies. When PT-141 activates these receptors, it initiates a downstream signaling cascade that converges on the neural circuits governing sexual desire.

In the PVN, MC4R activation triggers oxytocin release from parvocellular neurons that project to the spinal cord and limbic system. This oxytocin release is a key downstream mediator of the sexual arousal response — oxytocin has established roles in facilitating sexual response in both sexes, including genital vasocongestion in women and erection in men. MC4R activation in the MPOA contributes to increased sexual motivation and approach behavior. In the brainstem, MC4R-driven dopaminergic signaling amplifies reward valuation of sexual stimuli.

In women, the downstream neural output of PT-141’s hypothalamic activation produces increased genital vasocongestion (measured by vaginal photoplethysmography in clinical studies), heightened sensitivity to sexual stimuli, and — critically for HSDD treatment — increased subjective sexual desire and motivation. In the RECONNECT trials, both objective physiological and subjective self-report endpoints improved significantly versus placebo. In men, the neural output drives erection through the sacral parasympathetic pathway, producing erections independent of sexual stimulation — the spontaneous erection phenomenon documented in the original Arizona trials and the controlled Wessells studies.

The nausea and blood pressure effects of PT-141 are also MC4R-mediated, operating through different neural pathways: nausea through MC4R activation in the area postrema, and blood pressure elevation through MC4R-driven sympathetic outflow. These on-target adverse effects cannot be fully dissociated from the therapeutic effects with the same mechanism at the same receptor — they represent the cost of non-compartmentalized MC4R agonism across the CNS and brainstem.

PT-141 vs PDE5 Inhibitors: A Mechanistic Comparison

PT-141 (Bremelanotide) PDE5 Inhibitors (Sildenafil, Tadalafil)
Site of action Central — hypothalamus and limbic system Peripheral — penile/vaginal vascular smooth muscle
Target MC3R / MC4R — G-protein coupled receptors PDE5 enzyme — prevents cGMP breakdown
What it addresses Sexual desire and motivation deficit Mechanical erectile failure despite intact desire
Requires stimulation? No — generates central arousal signal spontaneously Yes — requires sexual stimulation to be active
Effectiveness with vascular disease Preserved — central mechanism bypasses vascular step Reduced — depends on functional vascular response
Efficacy in women Established — FDA-approved for HSDD in women Limited — trials in women largely inconclusive or negative
Cardiovascular interaction Raises BP transiently — avoid with nitrates Lowers BP — contraindicated with nitrates (severe hypotension risk)
FDA approval Yes — HSDD in premenopausal women (2019) Yes — erectile dysfunction in men; some female indications off-label

The mechanistic distinction matters clinically. A man who experiences erectile dysfunction because he has significant vascular disease and limited endothelial NO/cGMP signaling is a candidate for a PDE5 inhibitor — the problem is peripheral and the fix is peripheral. A man who experiences erectile dysfunction because his sexual desire has diminished and he cannot generate sufficient arousal to produce a reliable erection is a candidate for a melanocortin agonist — the problem is central and the fix is central. Many patients have both components. In that mixed presentation, PT-141 and a PDE5 inhibitor are mechanistically complementary: PT-141 generates the central arousal signal, the PDE5 inhibitor amplifies the vascular response. The combination has been used off-label in men and is sometimes described as having additive or synergistic effects, though no large controlled trial has formally studied the combination.

Key Research: The RECONNECT Trials

The pivotal evidence base for PT-141’s approval consists of two Phase III, randomized, placebo-controlled, double-blind trials known as the RECONNECT studies (Randomized, placebo-Controlled trials of bremelanotide for female sexual dysfunction). Both were published in Obstetrics and Gynecology in 2019 (Simon et al.) and formed the primary basis for FDA approval.

Trial Design

The two RECONNECT trials enrolled premenopausal women aged 22–55 with a diagnosis of HSDD (Trial 1, n=394) or female sexual arousal disorder (FSAD) with co-occurring HSDD (Trial 2, n=394) confirmed by structured diagnostic interview. Participants were randomized 1:1 to bremelanotide 1.75 mg SC or placebo, self-administered 45 minutes before anticipated sexual activity, as needed, over 24 weeks. Primary endpoints were change from baseline in the Female Sexual Function Index desire domain (FSFI-D) and change in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 (distress related to low sexual desire).

Efficacy Results

In Trial 1 (HSDD): bremelanotide produced a statistically significant improvement versus placebo on both primary endpoints. FSFI desire domain improved by 0.356 points more than placebo (p=0.0017); FSDS-DAO item 13 distress score improved by 0.244 points more than placebo (p=0.0005). In Trial 2 (FSAD/HSDD): FSFI desire improved by 0.338 points more than placebo (p=0.0065); FSDS-DAO item 13 improved by 0.295 points more than placebo (p<0.0001). Both trials met both co-primary endpoints.

Evidence context: The RECONNECT effect sizes are statistically significant but modest on standardized scales. The FSFI desire domain score difference of ~0.35 points on a 6-point scale represents a real but limited improvement. Importantly, approximately 25% of bremelanotide-treated participants were classified as treatment responders versus ~17% of placebo participants — a meaningful but not dramatic separation. These are the honest numbers. The FDA found them sufficient for approval in a condition with significant unmet need and no serious competing options.

Responder Analysis

The RECONNECT trials also reported responder analyses — patients who achieved a meaningful improvement threshold on both primary endpoints. Approximately 25% of bremelanotide-treated participants were defined as treatment responders versus 17% on placebo across both trials. The number needed to treat (NNT) for a meaningful response is approximately 12–13 — meaning for every 12–13 women treated, one achieves a meaningful response that placebo would not have provided. This is modest by oncology standards but clinically meaningful for a condition affecting quality of life and relationships, with no alternatives.

Evidence in Women: Approved Indication

PT-141 is the only FDA-approved drug for HSDD that acts through a central neural mechanism — all prior and concurrent treatments for female sexual dysfunction addressed either hormonal or peripheral vascular components. Its approval represents regulatory recognition that HSDD has a neurobiological basis amenable to pharmacological treatment targeting the central arousal circuitry directly.

Beyond the primary RECONNECT endpoints, secondary analyses showed improvements in satisfying sexual events (SSEs) per month — a pre-specified secondary endpoint. Women in the bremelanotide group reported approximately 0.5 additional SSEs per month compared to placebo across the trial period. Self-reported arousal, lubrication, and overall sexual function also improved on FSFI subscale analyses. Patient global impression scores showed greater improvement with bremelanotide versus placebo.

The approved indication is specifically for premenopausal women with acquired, generalized HSDD. The restriction to premenopausal women reflects the trial enrollment — postmenopausal women were excluded from RECONNECT. The acquired, generalized specification excludes lifelong HSDD (which may have different neurobiological basis) and situational HSDD (which may be better addressed through relationship or psychological intervention). Clinicians using PT-141 off-label in postmenopausal or situational HSDD are operating outside the evidence base of the approval.

Evidence in Men: Off-Label Use

PT-141’s use in men is entirely off-label. No approved indication exists for any male sexual dysfunction. The evidence base consists of Phase I/II controlled trials (primarily from the earlier intranasal formulation development program) and a body of published case series and observational data from clinical use.

The Wessells group at the University of Washington conducted the most rigorous early controlled studies. Using RigiScan monitoring (objective erectile function measurement), they demonstrated that MT-II and then PT-141 produced significantly greater erectile activity than placebo in men with both psychogenic and organic erectile dysfunction. A Phase II trial of intranasal PT-141 in 271 men with erectile dysfunction reported a statistically significant improvement in erectile function versus placebo, with response rates of approximately 60–70% in the PT-141 group versus 40–50% in the placebo group at the higher doses studied.

In clinical practice, PT-141 is used off-label in men for erectile dysfunction that is refractory to or incompletely responsive to PDE5 inhibitors, and for low sexual desire in men (male HSDD, a recognized but underdiagnosed condition). The subcutaneous injection format (1.75 mg) used in the approved women’s indication is the most common format used off-label in men; some compounding pharmacies produce lower doses (0.5–1.0 mg) that reduce nausea burden while preserving meaningful erectile and desire effects.

The combination of PT-141 with a PDE5 inhibitor is commonly used in men who have both desire and vascular components to their erectile dysfunction. This combination — addressing both central arousal generation and peripheral vascular amplification — is mechanistically rational and widely reported in the clinical community, though no large RCT has formally evaluated it. Anecdotally and in case series, the combination is reported to produce more reliable and complete erectile responses than either compound alone in men with mixed organic and psychogenic ED.

Evidence context: The male evidence base is Phase I/II — controlled and peer-reviewed, but not at the Phase III level that would support an approved indication. Clinicians prescribing PT-141 off-label for men are doing so based on a reasonable mechanism, early controlled data, and clinical experience, not on an approved Phase III evidence base. This is a meaningful distinction to understand when evaluating the male use case.

Common Claims versus Current Evidence

Claim What the Evidence Shows Verdict
“PT-141 is FDA-approved for women with low libido” Correct for acquired, generalized HSDD in premenopausal women. The approved indication is specific — not all low libido qualifies as HSDD under the approval criteria. Accurate with qualification
“PT-141 works like Viagra but better” Different mechanism, not directly comparable. Viagra addresses vascular erectile failure; PT-141 addresses central desire deficit. For desire-driven dysfunction, PT-141 may be more appropriate. For vascular-driven dysfunction, sildenafil is the more established choice. Neither is categorically better. Misleading — different mechanisms, different indications
“PT-141 is approved for men” No approved indication exists in men. Off-label use is practiced and has Phase I/II supporting evidence, but the FDA approval is women-only for HSDD. False — men’s use is entirely off-label
“PT-141 has no serious side effects” Nausea occurs in ~40% of treated women in trials. Transient hypertension is documented — the FDA label requires BP measurement before each dose and contraindicates use in patients with CV disease where transient BP elevation poses risk. Hyperpigmentation occurs with chronic use. False — several labeled safety concerns
“PT-141 tans the skin like MT-II” Minimal MC1R activity — substantially less tanning than MT-II. Hyperpigmentation (including facial) is noted as a labeled adverse effect with chronic use, but this is different from the intentional, whole-body tanning that MT-II produces. Mostly false — minimal tanning; some pigmentation with chronic use

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Safety, Risks, and Limitations

Nausea (Common, Dose-Dependent)

Nausea is the most frequently reported adverse event in the RECONNECT trials, occurring in approximately 40% of bremelanotide-treated participants versus 15% of placebo participants. It is MC4R-mediated through activation of the area postrema and is dose-dependent and time-limited — typically beginning 30–60 minutes after injection and resolving within 4–6 hours. Anti-nausea pretreatment with ondansetron is used off-label to reduce this burden; the FDA label does not specifically recommend pretreatment but notes nausea as a common labeled adverse event that may limit use.

Transient Hypertension (Clinically Significant)

Bremelanotide produces transient, dose-dependent blood pressure elevation — a direct MC4R-mediated autonomic effect. In the RECONNECT trials, mean maximum SBP increase was approximately 6 mmHg and mean maximum DBP increase was approximately 4 mmHg, typically occurring within 12 hours post-dose and resolving within 12 hours. While these mean changes are modest, individual peak responses can be more substantial. The FDA label requires blood pressure measurement before each dose and contraindicates use in patients with uncontrolled hypertension or cardiovascular disease where transient BP elevation poses meaningful risk. This is the most clinically important safety consideration for PT-141 — unlike nausea (unpleasant but not dangerous), BP elevation carries objective cardiovascular risk in susceptible patients.

Safety Alert

PT-141 is contraindicated in patients with known cardiovascular disease or uncontrolled hypertension. The FDA label explicitly requires BP measurement before each dose. For off-label use in men — where the CV risk profile may be different from the premenopausal women studied — this contraindication deserves particular attention. Do not use PT-141 with nitrates; unlike PDE5 inhibitors (which lower BP and interact dangerously with nitrates), PT-141 raises BP, but concurrent vasodilator use still warrants caution.

Hyperpigmentation

Focal hyperpigmentation — particularly of the face, breasts, and gums — is a labeled adverse event with chronic PT-141 use. This is a low-level MC1R effect (PT-141’s MC1R binding is minimal but not zero) that accumulates with repeated dosing over time. At the as-needed dosing regimen and maximum of 8 doses per month, this effect is rare in the clinical trial population, but it is more relevant for individuals using PT-141 more frequently off-label. The FDA label notes hyperpigmentation as a labeled adverse event and notes that it may not resolve after stopping treatment.

Flushing and Injection Site Reactions

Flushing (warmth, redness) occurs in approximately 20% of treated patients in trials — also MC4R-mediated autonomic effect. Injection site reactions (bruising, pain) are reported in a small percentage of patients. Both are generally mild and self-limiting.

Legal and Regulatory Status

PT-141 (bremelanotide, Vyleesi) is a Schedule V prescription drug in the United States, FDA-approved June 21, 2019, for acquired generalized HSDD in premenopausal women. It is not scheduled as a controlled substance under the Controlled Substances Act. In the EU and other major markets, bremelanotide does not currently hold marketing authorization for any indication. WADA: not prohibited. Men obtaining PT-141 via compounding pharmacies are using an off-label, non-approved formulation; the underlying active ingredient (bremelanotide) is an FDA-approved drug substance, but compounded preparations are not FDA-approved products.

Dosing and Delivery

Approved dose (women): 1.75 mg SC injection, administered approximately 45 minutes before anticipated sexual activity. Maximum one dose in 24 hours; maximum 8 doses per month. Inject into the abdomen or thigh. The Vyleesi auto-injector is a prefilled single-use device. If nausea or other side effects are unacceptable, there is no approved titration strategy — the 1.75 mg dose is the only approved strength.

Off-label use in men (compounded): Doses range from 0.5 mg to 2.0 mg SC, with most clinical practitioners starting at 0.5–1.0 mg and titrating based on response and tolerability. Lower starting doses substantially reduce nausea while preserving meaningful arousal effects for many patients. The compounded SC formulation is the most common; some practitioners use intranasal compounded preparations, though nasal bioavailability is variable and less studied for PT-141 than for MT-II.

Onset and duration: Onset of sexual arousal effects is typically 45–60 minutes post-injection; duration of effect is 6–12 hours. The blood pressure effect peaks at 2–4 hours and resolves within 12 hours. Nausea, if it occurs, begins at 30–60 minutes and typically resolves by 4–6 hours.

Delivery Routes in Self-Experimentation Communities

Route Community Use Evidence Key Notes
SC injection — approved Vyleesi (women) Prescription use; prescribed by gynecologists and sexual medicine specialists Phase III RECONNECT trials; FDA-approved BP measurement required before each dose; max 8/month
SC injection — compounded (men/off-label) Growing use via men’s health telehealth and compounding pharmacies Phase I/II controlled trials; extensive off-label clinical use data Lower starting doses (0.5 mg) reduce nausea while preserving effect
Intranasal — compounded Some clinical use; less common than SC injection; grey market nasal sprays exist Phase II nasal program demonstrated efficacy in men; bioavailability variable Dose uncertainty with intranasal route; all systemic risks present at absorbed doses

PT-141 is increasingly available through men’s health telehealth platforms that prescribe and ship compounded bremelanotide. This is currently legal for the prescribing physician as off-label use of an FDA-approved drug substance. Research peptide suppliers also sell PT-141 without prescription; this material is not pharmaceutical-grade and carries the usual quality uncertainty of unregulated peptide suppliers. Bacteriostatic water for injection is the correct reconstitution medium for any injectable PT-141. For anyone using PT-141 regularly, awareness of the blood pressure monitoring requirement and the nausea management strategies is more important than for most peptides given the direct cardiovascular risk flag on the FDA label.

Frequently Asked Questions

Q1: What is PT-141 and how is it different from Viagra?

A1: PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist that activates MC3R and MC4R in the hypothalamus and limbic system — the brain circuits that generate sexual desire. Viagra (sildenafil) works peripherally by improving blood flow to an already-aroused penis. PT-141 generates the central arousal signal itself; Viagra amplifies the vascular response to an existing signal. This is why PT-141 can work in men and women with desire-based dysfunction where Viagra has little effect, and why PT-141 is FDA-approved for women with HSDD while PDE5 inhibitors are not indicated for that condition.

Q2: What is HSDD and is PT-141 approved for it?

A2: Hypoactive sexual desire disorder (HSDD) is a persistent, distressing absence of sexual desire not explained by relationship problems, medications, or other medical conditions. PT-141 (Vyleesi) is FDA-approved for acquired, generalized HSDD in premenopausal women — the only approved drug for this indication that works through central neural arousal activation. The Phase III RECONNECT trials demonstrated statistically significant improvements in desire and distress scores versus placebo. The approval covers premenopausal women with the acquired, generalized subtype only; postmenopausal women and situational HSDD are outside the approved indication.

Q3: Is PT-141 approved for men?

A3: No. PT-141 has no FDA-approved indication in men. Off-label use for erectile dysfunction and male hypoactive sexual desire disorder is practiced via compounding pharmacies, supported by Phase I/II controlled trial data (particularly the Wessells group RigiScan studies) but not by a Phase III approval package. Men accessing PT-141 are using an off-label application with real mechanistic rationale and early-phase controlled evidence, but without the regulatory approval that the women’s indication carries.

Q4: What are the main side effects of PT-141?

A4: Nausea is the most common adverse event, occurring in approximately 40% of treated women in the RECONNECT trials — it is a direct MC4R effect mediated through the area postrema and is dose-dependent and time-limited (typically resolving within 4–6 hours). Transient hypertension is a clinically significant labeled adverse event: the FDA label requires blood pressure measurement before each dose and contraindicates use in patients with cardiovascular disease or uncontrolled hypertension. Flushing occurs in approximately 20% of patients. Hyperpigmentation (particularly facial) can occur with chronic use. These are all on-target MC4R effects, not allergic or idiosyncratic reactions.

Q5: How does PT-141 relate to Melanotan II?

A5: PT-141 was derived from Melanotan II (MT-II) research. In the 1990s, University of Arizona tanning trials with MT-II documented spontaneous erections and increased libido as a side effect — direct MC3R/MC4R activation by the non-selective pan-agonist. Palatin Technologies then developed PT-141 by modifying the MT-II structure to maximize MC3R/MC4R activity (sexual arousal) while minimizing MC1R activity (tanning). The result is a compound that retains the desired central arousal effect while shedding most of the tanning activity and the melanocytic nevi risk associated with MT-II’s strong MC1R agonism. PT-141 and MT-II are related but distinct compounds with meaningfully different receptor profiles and risk profiles.

Q6: Can PT-141 be combined with a PDE5 inhibitor like Viagra or Cialis?

A6: The combination is mechanistically rational and widely used off-label in men — PT-141 generates the central arousal signal (neural), the PDE5 inhibitor amplifies the peripheral vascular response (vascular). For men with mixed psychogenic and organic erectile dysfunction, addressing both the central desire component and the vascular response component simultaneously is a coherent approach. No large controlled trial has formally studied the combination. In practice, the combination is commonly reported to produce more reliable erectile responses than either compound alone in men with a mixed presentation. Blood pressure monitoring is relevant — PT-141 raises BP transiently while PDE5 inhibitors lower it, so concurrent use in cardiovascular risk patients warrants physician oversight.

Q7: How is PT-141 dosed and when should it be taken?

A7: The FDA-approved dose for women is 1.75 mg SC injection approximately 45 minutes before anticipated sexual activity. Maximum one dose per 24 hours; maximum 8 doses per month. The auto-injector (Vyleesi) is a prefilled single-use device for abdominal or thigh injection. Off-label compounded doses for men typically range from 0.5 mg to 2.0 mg SC, with many practitioners starting at 0.5–1.0 mg to reduce nausea while preserving arousal effects. Onset of effect is typically 45–60 minutes post-injection; duration 6–12 hours. The blood pressure elevation peaks at 2–4 hours. Measure blood pressure before each dose as directed by the FDA label.

PT-141 sits at the intersection of the melanocortin and sexual health clusters. Its direct mechanistic predecessors and relatives are Melanotan II (the parent compound from which PT-141 was derived) and afamelanotide (the MC1R-selective tanning derivative). For the full story of how PT-141’s mechanism was discovered, see the Melanotan II research overview. Within the Sexual Health & Hormonal cluster, PT-141 is the anchor compound — the only FDA-approved peptide specifically for sexual dysfunction. The table below shows all compounds in the cluster.

Summary and Key Takeaways

  • PT-141 (bremelanotide, Vyleesi) is FDA-approved for acquired, generalized HSDD in premenopausal women — the only approved drug for this indication that works through central neural activation of sexual desire rather than hormonal or vascular mechanisms.
  • Mechanism: MC3R/MC4R agonism in the hypothalamus and limbic system. Generates sexual desire and arousal centrally — distinct from and mechanistically complementary to PDE5 inhibitors, which work peripherally on vascular response.
  • Phase III RECONNECT trial data: statistically significant improvement on both co-primary endpoints (FSFI desire domain and FSDS-DAO distress score) in premenopausal women with HSDD. Effect sizes are modest but clinically meaningful in a condition with significant unmet need.
  • Off-label use in men is supported by Phase I/II controlled trial data showing improved erectile function versus placebo, including in men with organic erectile dysfunction. No Phase III trial in men; FDA approval is women-only.
  • Combination with PDE5 inhibitors in men is mechanistically rational (central + peripheral) and widely practiced, but not supported by a large controlled trial.
  • Safety: nausea (~40% in trials), transient hypertension (clinically significant — BP measurement required before each dose per FDA label), hyperpigmentation with chronic use, flushing. Contraindicated in CV disease or uncontrolled hypertension.
  • WADA: not prohibited. Prescription drug in the US; off-label use in men via compounding pharmacies is common and legal under physician supervision.
  • Origin story: discovered accidentally as a side effect of Melanotan II tanning research in Arizona in the 1990s. The specific compound PT-141 was engineered from MT-II to retain sexual arousal effects (MC3R/MC4R) while eliminating tanning effects (MC1R). Full development program: approximately 25 years from observation to FDA approval.
Edit
Compound Type Primary Target Half-Life FDA Status WADA Status Evidence Tier Sexual Health Mechanism Receptor Target FDA Approved Indication Key Differentiator
PT-141 (Bremelanotide) Synthetic heptapeptide (Ac-Nle-cyclo(Asp-His-D-Nal(2′)-Arg-Trp-Lys)-NH2, melanocortin agonist) MC1R / MC4R (melanocortin-4 receptor in hypothalamus) ~2–4 hours FDA-approved (Vyleesi, 2019 for female hypoactive sexual desire disorder — HSDD) Prohibited — S4 (Hormone analog / Melanocortin peptide agonist) Tier 1 — Approved Drug Central melanocortin pathway activation (hypothalamic appetite/sexual behavior integration); genital arousal signaling MC1R (skin pigmentation); MC4R (sexual desire, appetite centers in hypothalamus) Female HSDD (hypoactive sexual desire disorder) — FDA approved 2019. Subcutaneous injection (pre-coitus dosing) Only FDA-approved peptide for sexual dysfunction. Off-label use in males reported but not approved. Requires frequent pre-coitus dosing
Melanotan II (MT-II) Synthetic non-peptide cyclic melanocortin agonist (Ac-Nle-cyclo(Asp-His-D-Phe(4-I)-Arg-Trp-Lys)-NH2, similar to PT-141 but with iodinated D-Phe) MC1R / MC4R (melanocortin-4 receptor, broader activation than PT-141) ~4–6 hours Not FDA-approved (research/investigational compound) Prohibited — S4 (Hormone analog / Melanocortin peptide agonist) Tier 3 — Pilot / Limited Human Data Melanocortin pathway agonism; sexual arousal (reported in males and females); pigmentation/tanning (off-target effect) MC1R (skin) >> MC4R (hypothalamic sexual/appetite centers) — broad melanocortin activation No FDA indication (investigational). Off-label interest for erectile dysfunction and female sexual arousal Broader melanocortin agonism than PT-141. Significant tanning/pigmentation as off-target effect. Injectable only (research compound)
Leuprolide (Lupron) Synthetic decapeptide GnRH agonist (Ac-D-Leu(1)-Pro(2)-ethylamide-D-Trp(6)-LH-RH, synthetic LHRH analog) GnRH-R (gonadotropin-releasing hormone receptor; agonist-mediated desensitization at higher doses) ~3–4 hours (injection); ~1 month (depot formulations) FDA-approved (multiple indications: prostate cancer, endometriosis, precocious puberty, breast cancer palliative care) Prohibited — S2 (GnRH analog, hormone) Tier 1 — Approved Drug GnRH agonism → Initial LH/FSH surge → Downregulation → Testosterone suppression (chemical castration for cancer/endo); precocious puberty halting GnRH-R (pituitary gonadotroph cells); biphasic agonist-antagonist (flare then suppression) Prostate cancer (palliative), endometriosis, precocious puberty, uterine fibroids, breast cancer palliative FDA-approved since 1989. Extended-release formulations (1-, 3-, 6-, 12-month depot). No sexual enhancement indication; used for hormone suppression

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Selected References and Key Studies

  1. Simon JA, et al. Bremelanotide for hypoactive sexual desire disorder among women: a randomized, placebo-controlled, phase 3 clinical trial. Obstet Gynecol. 2019;134(5):899–908. PMID 31599840 — RECONNECT Trial 1
  2. Clayton AH, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325–37. PMID 27147596
  3. Wessells H, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 1998;52(6):1007–12. PMID 9836546
  4. Diamond LE, et al. A double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51–9. PMID 14963480
  5. Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909–17. PMID 31599839 — RECONNECT Trial 2
  6. King SH, et al. Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem. 2007;7(11):1098–106. PMID 17584130

Further Reading

Disclaimer

This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations. Nothing here should be interpreted as a recommendation to use PT-141 (bremelanotide) for any purpose.

PT-141 (Vyleesi) is an FDA-approved prescription medication approved only for acquired, generalized HSDD in premenopausal women. Its use requires physician evaluation and prescription. Off-label use in men has not received FDA approval and should be undertaken only under physician supervision. The blood pressure monitoring requirement in the FDA label is a clinically significant safety consideration — not a formality.

Compounded PT-141 obtained outside the pharmaceutical supply chain is not FDA-approved and quality is not guaranteed. Consult a qualified physician or sexual medicine specialist before considering PT-141.

Scroll to Top